Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs and Nivolumab in Metastatic Melanoma
NCT02652455Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2016
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Occurrence of Study Related Adverse Events at 27 months. Started Mar 2016; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02652455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652455.